Q2 2024 FibroGen Inc Earnings Call Transcript
Good day and welcome to the FibroGen second quarter 2024 earnings conference call. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to David DeLucia, VP of Investor Relations. Please go ahead.
Good afternoon, everyone. Thank you for joining today to discuss our second quarter 2024 financial and business results. I'm David DeLucia, Vice President of Corporate FP&A and Investor Relations at FibroGen.
Joining me on today's call are Thane Wettig, our Chief Executive Officer; Dr. Deyaa Adib, our Chief Medical Officer; Juan Graham, our Chief Financial Officer; Chris Chung, our Senior Vice President of China Operations, and Dr. John Hunter, our Chief Scientific Officer. Following our prepared remarks, we will open the call to your questions.
I would like to remind you that remarks made on today's call include forward-looking statements about FibroGen. Such statements may include, but are
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |